Clinical Trials Browser

Phase EARLY_PHASE1 × Interventional × durvalumab × Clear all

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Phase EARLY_PHASE1 Active not recruiting

11 enrolled 6 charts

Thyroid Neoplasms

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Phase EARLY_PHASE1 Terminated

17 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Phase EARLY_PHASE1 Completed

16 enrolled 8 charts

Anatomic Stage II Breast Cancer AJCC v8

NCT03818776 2024-02-15

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Phase EARLY_PHASE1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Phase EARLY_PHASE1 Withdrawn

Melanoma

NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Phase EARLY_PHASE1 Withdrawn

BreastOther neoplasm

Breast Cancer Female

NCT02802098 2020-06-19

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT03235869 2018-03-15

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Phase EARLY_PHASE1 Withdrawn

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous